Reappraising the stereotypes of diabetes in the modern diabetogenic environment

Nature Reviews Endocrinology

Volumn 5, Issue 9, 2009, Pages 483-489

  Wentworth, John M ^a   Fourlanos, Spiros ^a   Harrison, Leonard C ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTIINFLAMMATORY AGENT; CALCIUM; INTERLEUKIN 1BETA; OMEGA 3 FATTY ACID; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE MODEL; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RICKETS; VITAMIN D DEFICIENCY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; STEREOTYPING;

EID: 70349305566     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.149     Document Type: Review

References (69)

1. ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 32 (Suppl. 1), s62-s67 (2009).
2. Harrison, L. C. risk assessment, prediction and prevention of type 1 diabetes. Pediatr. Diabetes 2, 71-82 (2001).
3. Wenzlau, J. M. et al. The cation efflux transporter ZnT8 (slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl Acad. Sci. USA 104, 17040-17045 (2007).
4. Eisenbarth, G. S. & Pugliese, A. in Type 1 Diabetes: Molecular, Cellular and Clinical Immunology (ed. eisenbarth, G. s.) 2403-2407 (The Barbara Davis Center for Childhood Diabetes, Denver, 2007).
5. Florez, J. C. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J. Clin. Endocrinol. Metab. 93, 4633-4642 (2008).
6. Fourlanos, S. et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48, 2206-2212 (2005).
7. Gale, E. A. Declassifying diabetes. Diabetologia 49, 1989-1995 (2006).
8. Wilkin, T. J. Diabetes: 1 and 2, or one and the same Progress with the accelerator hypothesis. Pediatr. Diabetes 9, 23-32 (2008).
9. Fox, C. S. et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart study. Circulation 113, 2914-2918 (2006).
10. Gale, E. A. The rise of childhood type 1 diabetes in the 20th century. Diabetes 51, 3353-3361 (2002).
11. Fourlanos, S. et al. The rising incidence of type 1 diabetes is accounted for by cases with lowerrisk human leukocyte antigen genotypes. Diabetes Care 31, 1546-1549 (2008).
12. Bruining, G. J. Association between infant growth before onset of juvenile type1 diabetes and autoantibodies to iA2. Netherlands Kolibrie study group of childhood diabetes. Lancet 356, 655-656 (2000).
13. Hypponen, E. et al. Infant feeding, early weight gain, and risk of type 1 diabetes. Childhood Diabetes in Finland (DiMe) study Group. Diabetes Care 22, 1961-1965 (1999).
14. Couper, J. J. et al. Weight gain in early life predicts risk of islet autoimmunity in children with a firstdegree relative with type 1 diabetes. Diabetes Care 32, 94-99 (2009).
15. Fourlanos, S., Narendran, P. , Byrnes, G. B., Colman, P. G. & Harrison, L. C. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47, 1661-1667 (2004).
16. Mrena, S. et al. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 29, 662-667 (2006).
17. Xu, P. , Cuthbertson, D., Greenbaum, C., Palmer, J. P. & Krischer, J. P. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 30, 2314-2320 (2007).
18. Bingley, P. J., Mahon, J. L. & Gale, E. A. Insulin resistance and progression to type 1 diabetes in the european Nicotinamide Diabetes intervention Trial (eNDiT). Diabetes Care 31, 146-150 (2008).
19. Prentice, A. & Jebb, S. Energy intake/physical activity interactions in the homeostasis of body weight regulation. Nutr. Rev. 62, s98-s104 (2004).
20. Esposito, K. et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am. J. Clin. Nutr. 78, 1135-1140 (2003).
21. Qi, L. et al. Wholegrain, bran, and cereal fiber intakes and markers of systemic inflammation in diabetic women. Diabetes Care 29, 207-211 (2006).
22. Odegaard, A. O. & Pereira, M. A. Trans fatty acids, insulin resistance, and type 2 diabetes. Nutr. Rev. 64, 364-372 (2006).
23. Elliott, S. S., Keim, N. L., Stern, J. S., Teff, K. & Havel, P. J. Fructose, weight gain, and the insulin resistance syndrome. Am. J. Clin. Nutr. 76, 911-922 (2002).
24. Yamagishi, S., Ueda, S. & Okuda, S. Food derived advanced glycation end products (AGes): a novel therapeutic target for various disorders. Curr. Pharm. Des. 13, 2832-2836 (2007).
25. Bach, J. F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911-920 (2002).
26. Strachan, D. P. Hay fever, hygiene, and household size. BMJ 299, 1259-1260 (1989).
27. Pozzilli, P. , signore, A., Williams, A. J. & Beales, P. E. NOD mouse colonies around the world recent facts and figures. Immunol. Today 14, 193-196 (1993).
28. Funda, D. P. , Fundova, P. & Harrison, L. C. Microfloradependency of selected diabetes preventive diets: germfree and exgermfree monocolonized NOD mice as models for studying environmental factors in type 1 diabetes [abstract Ms11.4]. In Proc. 13th Int. Cong. Immunol. 16 (Brazilian society for immunology, rio de Janeiro, Brazil, 2007).
29. Harrison, L. C. et al. Type 1 diabetes: lessons for other autoimmune diseases J. Autoimmun. 31, 306-310 (2008).
30. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
31. Turnbaugh, P. J. et al. An obesityassociated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
32. Creely, S. J. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292, e740-e747 (2007).
33. Nowson, C. A. & Margerison, C. Vitamin D intake and vitamin D status of Australians. Med. J. Aust. 177, 149-152 (2002).
34. Holick, M. F. & Chen, T. C. Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87, 1080s-1086s (2008).
35. Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R. & virtanen, S. M. Intake of vitamin D and risk of type 1 diabetes: a birth cohort study. Lancet 358, 1500-1503 (2001).
36. Vieth, R. Vitamin D supplementation, 25hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 69, 842-856 (1999).
37. [No authors listed] vitamin D supplementation in early childhood and risk for Type i (insulin dependent) diabetes mellitus. The eUrODiAB substudy 2 study Group. Diabetologia 42, 51-54 (1999).
38. Stene, L. C., Joner, G. & Norwegian Childhood Diabetes study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhoodonset type 1 diabetes: a large, populationbased, casecontrol study. Am. J. Clin. Nutr. 78, 1128-1134 (2003).
39. Scragg, R., Sowers, M. & Bell, C. Serum 25hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition examination survey. Diabetes Care 27, 2813-2818 (2004).
40. Borissova, A. M., Tankova, T. , Kirilov, G., Dakovska, L. & Kovacheva, R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int. J. Clin. Pract. 57, 258-261 (2003). (Pubitemid 36700706)
41. Inomata, S., Kadowaki, S., Yamatani, T. , Fukase, M. & Fujita, T. Effect of 1α (OH) vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner. Res. 1, 187-192 (1986).
42. Chiu, K. C., Chu, A., Go, V. L. & saad, M. F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 79, 820-825 (2004).
43. Pittas, A. G., Harris, S. S., Stark, P. C. & DawsonHughes, B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30, 980-986 (2007).
44. WesterterpPlantenga, M. S., Van Marken Lichtenbelt, W. D., Cilissen, C. & Top, S. Energy metabolism in women during short exposure to the thermoneutral zone. Physiol. Behav. 75, 227-235 (2002).
45. Tasali, E., Mokhlesi, B. & van Cauter, E. Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest 133, 496-506 (2008).
46. Bonnet, M. H. & Arand, D. L. We are chronically sleepdeprived. Sleep 18, 908-911 (1995).
47. Agras, W. S., Hammer, L. D., McNicholas, F. & Kraemer, H. C. Risk factors for childhood overweight: a prospective study from birth to 9.5 years. J. Pediatr. 145, 20-25 (2004).
48. Hasler, G. et al. The association between short sleep duration and obesity in young adults: a 13year prospective study. Sleep 27, 661-666 (2004).
49. Ayas, N. T. et al. A prospective study of self reported sleep duration and incident diabetes in women. Diabetes Care 26, 380-384 (2003).
50. Spiegel, K., Leproult, R. & van Cauter, E. Impact of sleep debt on metabolic and endocrine function. Lancet 354, 1435-1439 (1999).
51. Spiegel, K., Tasali, E., Penev, P. & van Cauter, E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann. Intern. Med. 141, 846-850 (2004).
52. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
53. Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27, 813-823 (2004).
54. Weisberg, S. P. et al. CCr2 modulates inflammatory and metabolic effects of highfat feeding. J. Clin. Invest. 116, 115-124 (2006).
55. Hevener, A. L. et al. Macrophage PPArγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117, 1658-1669 (2007).
56. Odegaard, J. I. et al. Macrophagespecific PPArγ controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007).
57. Patsouris, D. et al. Ablation of CD11positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell. Metab. 8, 301-309 (2008).
58. Laybutt, D. R. et al. Endoplasmic reticulum stress contributes to β cell apoptosis in type 2 diabetes. Diabetologia 50, 752-763 (2007).
59. Ehses, J. A. et al. Increased number of islet associated macrophages in type 2 diabetes. Diabetes 56, 2356-2370 (2007).
60. Hutchings, P. et al. Transfer of diabetes in mice prevented by blockade of adhesionpromoting receptor on macrophages. Nature 348, 639-642 (1990).
61. Devaraj, S. et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55, 774-779 (2006).
62. Wang, X. et al. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J. Immunol. 180, 1929-1937 (2008).
63. Ebstein, W. Zur therapie des diabetes mellitus, insbesondere uber die anwendeng der salicylauren natron bei demselben [German]. Berl. Klin. Wochenschr. 13, 337-340 (1876).
64. Williamson, R. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br. Med. J. 1, 760-762 (1901).
65. Hundal, R. S. et al. Mechanism by which high dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321-1326 (2002).
66. Ofei, F., Hurel, S., Newkirk, J., Sopwith, M. & Taylor, R. Effects of an engineered human antiTNFα antibody (CDP571) on insulin sensitivity and glycemic control in patients with NiDDM. Diabetes 45, 881-885 (1996).
67. Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N. & Drosos, A. A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64, 765-766 (2005).
68. Larsen, C. M. et al. Interleukin1receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
69. Stender, S., Dyerberg, J. & Astrup, A. High levels of industrially produced trans fat in popular fast foods. N. Engl. J. Med. 354, 1650-1652 (2006).